GlassScriptPhysician profile
John M Seeley
NPI 1649207135
$10,640.92
in general payments reported to CMS, 2019-2025
51 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,853 · 2020: $1,292 · 2021: $2,662 · 2022: $3,547 · 2023: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $286.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,009.50 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $816.29 | 2019-2023 | |
| Abbvie INC. | $815.26 | 2019-2023 | Ubrelvy, Duopa |
| Biogen, INC. | $630.83 | 2019-2022 | |
| Emd Serono, INC. | $575.81 | 2019-2023 | Mavenclad |
| Genzyme Corporation | $517.19 | 2019-2023 | |
| Ucb, INC. | $454.34 | 2019-2023 | Briviact |
| Amgen INC. | $429.81 | 2019-2022 | |
| Lilly USA, LLC | $350.22 | 2019-2022 | |
| Genentech USA, INC. | $342.22 | 2019-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $341.42 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $265.34 | 2019-2022 | |
| Grifols USA, LLC | $247.90 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $229.12 | 2019-2023 | Nuplazid |
| Sk Life Science, INC. | $224.04 | 2020-2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Seeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.